Document Detail

Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report.
MedLine Citation:
PMID:  4066227     Owner:  NLM     Status:  MEDLINE    
Neurotoxicity is a well-recognized and commonly observed side effect associated with the use of vincristine sulfate in cancer chemotherapy. The clinical manifestations of vincristine neuropathy cover a wide spectrum of peripheral neurologic dysfunctions that have been described to be reversible and cumulative in most instances (1, 2). Paresthesias, loss of tendon reflexes, and progressive weakness are the most common clinical features (3, 4). Sensory impairment, cranial nerve palsies, gastrointestinal disturbances, and autonomic dysfunctions including atonic bladder, impotence, and orthostatic hypotension may occur (5). Acute CNS complications, usually presenting as generalized seizures, are extremely rare and only a few cases have been reported which were without underlying biochemical or structural abnormalities (1, 5-9). We describe the case of a woman with multiple myeloma, who developed fulminant encephalopathy following 4 days of continuous vincristine, adriamycin, and day 1-4 pulse dexamethasone (VAD) combination therapy.
W Scheithauer; H Ludwig; E Maida
Related Documents :
18194287 - Memantine and nmda antagonism for chronic migraine: a potentially novel therapeutic app...
3624987 - Ulnar nerve laceration--a complication of carpal tunnel decompression: case report and ...
23587367 - Bmc dermatology reviewer acknowledgement, 2012.
11922717 - Operative findings in cases of trigeminal neuralgia without vascular compression: propo...
17873587 - Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic re...
11987957 - Subungual melanoma in situ: two independent streaks in one nail bed.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Investigational new drugs     Volume:  3     ISSN:  0167-6997     ISO Abbreviation:  Invest New Drugs     Publication Date:  1985  
Date Detail:
Created Date:  1986-01-03     Completed Date:  1986-01-03     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  315-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use
Brain Diseases / chemically induced*
Dexamethasone / administration & dosage,  adverse effects
Doxorubicin / administration & dosage,  adverse effects
Middle Aged
Multiple Myeloma / drug therapy
Vincristine / administration & dosage,  adverse effects
Reg. No./Substance:
0/VAD I protocol; 23214-92-8/Doxorubicin; 50-02-2/Dexamethasone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeast...
Next Document:  The use of programmed electrical stimulation to assess the fibrillatory propensity of ionic and noni...